《中癥症泰》2020年第30卷第1期 20 LANFRANCA M P, ZHANG Y, GIRGIS A, et al. Interleukin 22 blinded, randomised controlled phase 2/3 trial [J].Lancet ignaling regulates acinar cell plasticity to promote pancreatic Gastroenterol Hepatol. 2019.4(3): 199-207. tumor development in mice [J]. Gastroenterology, 2019 [35] RENARD E, DANCER P A, PORTAL C, et al. Design of Epub ahead of print bimodal ligands of neurotensin reeeptor I for PET imaging and [21] RAHN S BARBOSA P D MOLLER J L et al. Inflammation fluorescenee-guided surgery of pancreatic eancer [J] associated pancreatic tumorigenesis: upregulation of succinate Chem, 2019. Epub ahead of print dehydrogenase(subunit B)reduces cell growth of pancreatic [36] YUE Y, QIAN W, LI J et al. 2'-hydroxyflavanone inhibit al epithelial cells [J]. Cancers(Basel), 2019, 12(1): E42. the progression of pancreatic cancer cells and sensitizes the 22] LI J. YUAN S NORGARD R J et al. Tumor cell-intrinsic chemosensitivity of EGFR inhibitors via repressing STAT3 USP22 suppresses antitumor immunity in pancreatic caneer signaling [J]. Cancer Lett, 2019. Epub ahead of print [J].Cancer Immunol Res, 2019. Epub ahead of print] [37 FLORIO R VESCHI S DI GIACOMO V et al.The [23 ZHANG Y. XU J HUA J et al. A PD-L2-based immune benzimidazole-based anthelmintic parbendazole: a repurposed drug candidate that synergizes with gemcitabine in pancreatic ductal adenocarcinoma [J]. J Immunother Cancer 2019. 7(1): cancer[J]. Cancers(Basel). 2019. 11(12):E2042 [38 VIVALDI C FORNARO L VASILE E. FOLFIRINOX adjuvant [24] ENGLE DD. TIRIAC H. RIVERA K D, et al. The glycan therapy for pancreatic cancer [J]. N Engl J Med, 2019, CA19-9 promotes pancreatitis and pancreatic cancer in mice 80(12:1187-1188 [J]. Science,2019.3646446:1156-1162 [39] LOF S. KORREL M. VAN HILST J. et al. Impact of neoadjuvant 25] RIQUELME E. ZHANG Y, ZHANG L et al. Tumor microbiome therapy in resected pancreatic ductal adenocarcinoma of the pancreatic body or tail on surgical and oncological outcome:a [J].cl.2019.178(4795-806-12 propensity-score matched multicenter study [J]. Ann Surg [26] AYKUT B. PUSHALKAR S CHEN R, et al. The funga Oncol, 2019. Epub ahead of print mycobiome promotes pancreatic oncogenesis via activation of [40] MACEDO F 1, RYON E, MAITHEL S K, et al. Survival Nare.2019.574077264-267 outcomes associated with clinical and pathological response [27]KNIGHT J C. BAGUNA TORRES J GOLDIN R, et al. Early llowing neoadjuvant FOLFIRINOX or gemcitabine/nab- detection in a mouse model of pancreatic cancer by imaging paclitaxel chemotherapy in resected pancreatic cancer [J] DNA damage response signalling [J].J Nuel Med. 2019 nn surg.2019.2703:400-413 L Epub ahead of print [41] MICHELAKOS T, PERGOLINI I, CASTILLO C F et al 28] VENKAT R. EDIL B H, SCHULICK R D et al. Laparoscopic Predictors of resectability and survival in patients wit ital pancreatectomy is associated with significantly less overall borderline and locally advanced pancreatic cancer who morbidity compared to the open technique: a systematic review underwent neoadjuvant treatment with FOLFIRINOX [J] and meta-analysis [J]. Ann Surg. 2012. 255(6): 1048-1059 rg2019.2694:733- [ 29] RAMIREZ P T, FRUMOVITZ M PAREJA R, et al. Minimally [42] TRUTY M J. KENDRICK M L. NAGORNEY D M,et al. Factors invasive versus abdominal radical hysterectomy for cervical predicting response, perioperative outcomes, and survival cancer[J]. N Engl j Med.2018.37920:1895-1904 following total neoadjuvant therapy for borderline/locally 30] MELAMED A. MARGUL D J. CHEN L, et al. Survival after advanced pancreatic cancer [J]. Ann Surg, 2019. Epub inimally invasive radical hysterectomy for early-stage cervical cancer[J]. N Engl j Med,2018,379020):1905-1914 [43] NGUYEN A M. ZHOU J, SICAIROS B, et al. Upregulation 31] POVES 1. BURDIO F, MORATO O, et al. Comparison of of CD73 confers aequired radioresistance and is required for perioperative outcomes between laparoscopic and open approach maintaining irradiation-selected pancreatic cancer cells in a for pancreatoduodenectomy: the PADULAP randomized mesenchymal state [J]. Mol Cell Proteomics, 2019.[ Epub [32] LIU M, JIS, XU W, et al. Laparoscopic pancreaticoduodenectomy: [44JWANG K. ZHAN Y, HUYNH N, et al. Inhibition of PAKI are the best times coming? [J]. World J Surg Oncol, 2019 suppresses pancreatic cancer by stimulation of anti-tumour 17(1):81 munity through down-regulation of PD-L1 [J].Cancer 33] WANG M, PENG B, LIU J, et al. Practice patterns Lett,2019.[ Epub ahead of print and perioperative outcomes of laparoscopie [45] GOLAN T HAMMEL P. RENI M et al. Maintenance olaparib pancreaticoduodenectomy in China: a retrospective multicenter for germline BRCA-mutated metastatic pancreatic analysis of 1 029 patients [J]. Ann Surg, 2019. Epub ahead N Engl j Med.2019.381(4):317-327 of print [46]NETWORK. NCCN Clinical Practice Guidelines in Oncology 34 VAN HILST J, DE ROOI T BOSSCHA K, et al. Laparoscopi PancreaticAdenocarcinoma[eb/ol].httPs//www.ncen.org. versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient- [47]GOLDSTEIN J B. ZHAO L WANG X, et al.G《中国癌症杂志》2020年第30卷第1期 9 ［20］ LANFRANCA M P, ZHANG Y, GIRGIS A, et al. Interleukin 22 signaling regulates acinar cell plasticity to promote pancreatic tumor development in mice［J］. Gastroenterology, 2019. ［Epub ahead of print］ ［21］ RAHN S, BARBOSA P D, MOLLER J L, et al. Inflammation associated pancreatic tumorigenesis: upregulation of succinate dehydrogenase (subunit B) reduces cell growth of pancreatic ductal epithelial cells［J］. Cancers (Basel), 2019, 12(1): E42. ［22］ LI J, YUAN S, NORGARD R J, et al. Tumor cell-intrinsic USP22 suppresses antitumor immunity in pancreatic cancer ［J］. Cancer Immunol Res, 2019. ［Epub ahead of print］ ［23］ ZHANG Y, XU J, HUA J, et al. A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma［J］. J Immunother Cancer, 2019, 7(1): 233. ［24］ ENGLE D D, TIRIAC H, RIVERA K D, et al. The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice ［J］. Science, 2019, 364(6446): 1156-1162. ［25］ RIQUELME E, ZHANG Y, ZHANG L, et al. Tumor microbiome diversity and composition influence pancreatic cancer outcomes ［J］. Cell, 2019, 178(4): 795-806. e12. ［26］ AYKUT B, PUSHALKAR S, CHEN R, et al. The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL［J］. Nature, 2019, 574(7777): 264-267. ［27］ KNIGHT J C, BAGUNA TORRES J, GOLDIN R, et al. Early detection in a mouse model of pancreatic cancer by imaging DNA damage response signalling［J］. J Nucl Med, 2019. ［Epub ahead of print］ ［28］ VENKAT R, EDIL B H, SCHULICK R D, et al. Laparoscopic distal pancreatectomy is associated with significantly less overall morbidity compared to the open technique: a systematic review and meta-analysis［J］. Ann Surg, 2012, 255(6): 1048-1059. ［29］ RAMIREZ P T, FRUMOVITZ M, PAREJA R, et al. Minimally invasive versus abdominal radical hysterectomy for cervical cancer［J］. N Engl J Med, 2018, 379(20): 1895-1904. ［30］ MELAMED A, MARGUL D J, CHEN L, et al. Survival after minimally invasive radical hysterectomy for early-stage cervical cancer［J］. N Engl J Med, 2018, 379(20): 1905-1914. ［31］ POVES I, BURDIO F, MORATO O, et al. Comparison of perioperative outcomes between laparoscopic and open approach for pancreatoduodenectomy: the PADULAP randomized controlled trial［J］. Ann Surg, 2018, 268(5): 731-739. ［32］ LIU M, JI S, XU W, et al. Laparoscopic pancreaticoduodenectomy: are the best times coming?［J］. World J Surg Oncol, 2019, 17(1): 81. ［33］ WANG M, PENG B, LIU J, et al. Practice patterns a n d p e r i o p e r a t i v e o u t c o m e s o f l a p a r o s c o p i c pancreaticoduodenectomy in China: a retrospective multicenter analysis of 1 029 patients［J］. Ann Surg, 2019. ［Epub ahead of print］ ［34］ VAN HILST J, DE ROOIJ T, BOSSCHA K, et al. Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient￾blinded, randomised controlled phase 2/3 trial［J］. Lancet Gastroenterol Hepatol, 2019, 4(3): 199-207. ［35］ RENARD E, DANCER P A, PORTAL C, et al. Design of bimodal ligands of neurotensin receptor 1 for PET imaging and fluorescence-guided surgery of pancreatic cancer［J］. J Med Chem, 2019. ［Epub ahead of print］ ［36］ YUE Y, QIAN W, LI J, et al. 2’-hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensitivity of EGFR inhibitors via repressing STAT3 signaling［J］. Cancer Lett, 2019. ［Epub ahead of print］ ［37］ FLORIO R, VESCHI S, DI GIACOMO V, et al. The benzimidazole-based anthelmintic parbendazole: a repurposed drug candidate that synergizes with gemcitabine in pancreatic cancer［J］. Cancers (Basel), 2019,11(12): E2042. ［38］ VIVALDI C, FORNARO L, VASILE E. FOLFIRINOX adjuvant therapy for pancreatic cancer［J］. N Engl J Med, 2019, 380(12): 1187-1188. ［39］ LOF S, KORREL M, VAN HILST J, et al. Impact of neoadjuvant therapy in resected pancreatic ductal adenocarcinoma of the pancreatic body or tail on surgical and oncological outcome: a propensity-score matched multicenter study［J］. Ann Surg Oncol, 2019. ［Epub ahead of print］ ［40］ MACEDO F I, RYON E, MAITHEL S K, et al. Survival outcomes associated with clinical and pathological response following neoadjuvant FOLFIRINOX or gemcitabine/nab￾paclitaxel chemotherapy in resected pancreatic cancer［J］. Ann Surg, 2019, 270(3): 400-413. ［41］ MICHELAKOS T, PERGOLINI I, CASTILLO C F, et al. Predictors of resectability and survival in patients with borderline and locally advanced pancreatic cancer who underwent neoadjuvant treatment with FOLFIRINOX［J］. Ann Surg, 2019, 269(4): 733-740. ［42］ TRUTY M J, KENDRICK M L, NAGORNEY D M, et al. Factors predicting response, perioperative outcomes, and survival following total neoadjuvant therapy for borderline/locally advanced pancreatic cancer［J］. Ann Surg, 2019. ［Epub ahead of print］ ［43］ NGUYEN A M, ZHOU J, SICAIROS B, et al. Upregulation of CD73 confers acquired radioresistance and is required for maintaining irradiation-selected pancreatic cancer cells in a mesenchymal state［J］. Mol Cell Proteomics, 2019. ［Epub ahead of print］ ［44］ WANG K, ZHAN Y, HUYNH N, et al. Inhibition of PAK1 suppresses pancreatic cancer by stimulation of anti-tumour immunity through down-regulation of PD-L1［J］. Cancer Lett, 2019. ［Epub ahead of print］ ［45］ GOLAN T, HAMMEL P, RENI M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer［J］. N Engl J Med, 2019, 381(4): 317-327. ［46］ NETWORK. NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma［EB/OL］. https://www.nccn.org, 2020. ［47］ GOLDSTEIN J B, ZHAO L, WANG X, et al. Germline DNA